Do PBMs, drug market brokers, have a stranglehold on prices that even Congress can’t break?

  • 📰 USATODAY
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

Drugmakers, pharmacies and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?

The FTC under President Joe Biden has switched course, at least partly because of the arrival of Chair Lina Khan, a vigorous proponent of antitrust policy who launched an investigation of the PBMs last June.

And her reimbursements are “beyond low,” Seyfarth said. She laughed when asked whether contract terms with the PBMs were negotiable. “You aren’t negotiating anything,” she said. “It’s take it or leave it.” In October 2021, St. Clair’s treatment for a rare, non-smoking-related lung cancer was delayed three weeks after PBM giant Express Scripts insisted her prescription be filled by Accredo, the mail-order pharmacy it owns.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 100. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Do PBMs, drug market brokers, have a stranglehold on prices that even Congress can’t break?Drugmakers, pharmacies and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
Source: USATODAY - 🏆 100. / 63 Read more »